4-CMTB

4-CMTB (also known as AMG-7703) is a selective, small-molecule allosteric agonist and positive allosteric modulator (ago-PAM) of free fatty acid receptor 2 (FFA2/GPR43). Originally identified by Amgen, the compound binds to an allosteric site on FFA2 distinct from the orthosteric site of endogenous short-chain fatty acids (SCFAs), showing positive cooperativity with SCFAs like propionate and acetate. 4-CMTB stimulates intracellular calcium mobilization and inhibits cAMP accumulation through G protein-coupled signaling pathways. Although developed preclinically for the treatment of metabolic and inflammatory disorders (such as obesity and type 2 diabetes) by inhibiting lipolysis, its development was discontinued due to poor pharmacokinetic properties and low solubility. It is now widely utilized as a pharmacological research tool to study FFA2-mediated signaling and physiological functions.

Other names

(±)-4-CMTB2-(4-chlorophenyl)-3-methyl-N-(1,3-thiazol-2-yl)butanamide4-chloro-α-(1-methylethyl)-N-2-thiazolyl-benzeneacetamide4-chloro-α-(1-methylethyl)-N-2-thiazolylbenzeneacetamideBenzeneacetamide, 4-chloro-α-(1-methylethyl)-N-2-thiazolyl-phenylacetamide 1phenylacetamide1phenylacetamide-1